Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-19.
Status change: Not Yet Recruiting → Recruiting 2026-03-18
Trial Details
NCT Number NCT07371455
Lead Sponsor Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
Conditions Ischemic Stroke
Enrollment 76 participants
Start Date 2026-03-13
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20